FDA Approves Treatment Protocol for Use of Glucocerebrosidase
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Treatment Protocol for Use of Glucocerebrosidase

NEW YORK -- August 17, 2009 -- The US Food and Drug Administration (FDA) has approved Protalix’s treatment protocol for the use of the plant-cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease.

The treatment protocol allows physicians and other providers to treat patients with Gaucher disease with GCD in the United States while studies of GCD continue.

Prior to accepting the protocol, the FDA reviewed available data from on-going phase 3 clinical development programs.

The treatment protocol is a multicentre, open-label trial designed to allow physicians and other providers to treat patients with Gaucher disease with GCD during the expected shortage of imiglucerase (Cerezyme) and thereafter.

The treatment protocol allows patients enrolled in the protocol to continue being treated with GCD until its anticipated marketing approval from the FDA.

SOURCE: Protalix BioTherapeutics

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities